Market Cap
US$13.4b
Last Updated
2021/01/23 23:32 UTC
Data Sources
Company Financials +
Executive Summary
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record and good value.
Similar Companies
Share Price & News
How has DaVita's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DVA is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: DVA's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
0.7%
DVA
-0.3%
US Healthcare
2.3%
US Market
1 Year Return
43.8%
DVA
16.2%
US Healthcare
23.7%
US Market
Return vs Industry: DVA exceeded the US Healthcare industry which returned 16.2% over the past year.
Return vs Market: DVA exceeded the US Market which returned 23.7% over the past year.
Shareholder returns
| DVA | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.7% | -0.3% | 2.3% |
| 30 Day | 3.9% | 5.3% | 4.7% |
| 90 Day | 31.3% | 10.6% | 14.5% |
| 1 Year | 43.8%43.8% | 17.6%16.2% | 26.5%23.7% |
| 3 Year | 51.2%51.2% | 29.1%23.6% | 45.0%35.4% |
| 5 Year | 78.2%78.2% | 93.4%79.1% | 126.2%100.9% |
Long-Term Price Volatility Vs. Market
How volatile is DaVita's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is DaVita (NYSE:DVA) A Risky Investment?3 weeks ago | Simply Wall St
Should We Be Delighted With DaVita Inc.'s (NYSE:DVA) ROE Of 34%?1 month ago | Simply Wall St
Can You Imagine How DaVita's (NYSE:DVA) Shareholders Feel About The 62% Share Price Increase?Valuation
Is DaVita undervalued compared to its fair value and its price relative to the market?
29.3%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DVA ($119.59) is trading below our estimate of fair value ($168.92)
Significantly Below Fair Value: DVA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DVA is good value based on its PE Ratio (17.9x) compared to the US Healthcare industry average (30x).
PE vs Market: DVA is good value based on its PE Ratio (17.9x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: DVA is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: DVA is overvalued based on its PB Ratio (8.6x) compared to the US Healthcare industry average (3.5x).
Next Steps
Future Growth
How is DaVita forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
5.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVA's forecast earnings growth (5.5% per year) is above the savings rate (2%).
Earnings vs Market: DVA's earnings (5.5% per year) are forecast to grow slower than the US market (21.6% per year).
High Growth Earnings: DVA's earnings are forecast to grow, but not significantly.
Revenue vs Market: DVA's revenue (3% per year) is forecast to grow slower than the US market (10.6% per year).
High Growth Revenue: DVA's revenue (3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DVA's Return on Equity is forecast to be very high in 3 years time (52.2%).
Next Steps
Past Performance
How has DaVita performed over the past 5 years?
2.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVA has high quality earnings.
Growing Profit Margin: DVA's current net profit margins (7.2%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: DVA's earnings have grown by 2.1% per year over the past 5 years.
Accelerating Growth: DVA's earnings growth over the past year (33.4%) exceeds its 5-year average (2.1% per year).
Earnings vs Industry: DVA earnings growth over the past year (33.4%) exceeded the Healthcare industry 20.7%.
Return on Equity
High ROE: Whilst DVA's Return on Equity (34.37%) is high, this metric is skewed due to their high level of debt.
Next Steps
Financial Health
How is DaVita's financial position?
Financial Position Analysis
Short Term Liabilities: DVA's short term assets ($3.4B) exceed its short term liabilities ($2.5B).
Long Term Liabilities: DVA's short term assets ($3.4B) do not cover its long term liabilities ($11.5B).
Debt to Equity History and Analysis
Debt Level: DVA's debt to equity ratio (253.7%) is considered high.
Reducing Debt: DVA's debt to equity ratio has increased from 146.9% to 253.7% over the past 5 years.
Debt Coverage: DVA's debt is well covered by operating cash flow (28%).
Interest Coverage: DVA's interest payments on its debt are well covered by EBIT (5.5x coverage).
Balance Sheet
Next Steps
Dividend
What is DaVita current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DVA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.7yrs
Average management tenure
CEO
Javier Rodriguez (49 yo)
1.58yrs
Tenure
US$16,853,460
Compensation
Mr. Javier J. Rodriguez serves as Director at Gilead Sciences, Inc. since June 2020. He has been Chief Executive Officer and Executive Director of DaVita Inc. since June 1, 2019. Mr. Rodriguez has been the...
CEO Compensation Analysis
Compensation vs Market: Javier's total compensation ($USD16.85M) is above average for companies of similar size in the US market ($USD10.57M).
Compensation vs Earnings: Javier's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.58yrs | US$16.85m | 0.12% $ 15.5m | |
| CFO & Treasurer | 3.92yrs | US$6.54m | 0.011% $ 1.5m | |
| Chief Legal Officer | 4.67yrs | US$5.08m | 0.0096% $ 1.3m | |
| Chief Operating Officer of Kidney Care | 6.83yrs | US$13.29m | 0.039% $ 5.2m | |
| Group Vice President of Purchasing & Public Affairs | 9.5yrs | US$3.81m | 0.0049% $ 655.0k | |
| Chief Accounting Officer | 0.83yr | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Chief Compliance Officer | 2.83yrs | no data | 0.0023% $ 310.7k | |
| Vice President of Marketing & Communications | no data | no data | no data | |
| Chief People Officer | no data | no data | no data | |
| Executive Vice President of Global Operations | 5.33yrs | no data | no data | |
| Chief Medical Officer - Saudi Operations | 6.58yrs | no data | no data |
4.7yrs
Average Tenure
51.5yo
Average Age
Experienced Management: DVA's management team is considered experienced (4.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.58yrs | US$16.85m | 0.12% $ 15.5m | |
| Independent Director | 20.17yrs | US$295.02k | 0.055% $ 7.3m | |
| Independent Director | 0.33yr | no data | 0.00026% $ 34.8k | |
| Director | 13.83yrs | US$5.34m | 0.017% $ 2.3m | |
| Independent Director | 5.25yrs | US$387.77k | 0.0087% $ 1.2m | |
| Independent Director | 13.5yrs | US$286.27k | 0.010% $ 1.3m | |
| Independent Director | 4.5yrs | US$280.27k | 0.0078% $ 1.0m | |
| Independent Chairman | 0.58yr | US$380.77k | 0.017% $ 2.3m | |
| Independent Director | 0.33yr | no data | 0.00032% $ 42.9k |
4.5yrs
Average Tenure
62yo
Average Age
Experienced Board: DVA's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DVA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
DaVita Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: DaVita Inc.
- Ticker: DVA
- Exchange: NYSE
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$13.394b
- Shares outstanding: 112.00m
- Website: https://www.davita.com
Number of Employees
Location
- DaVita Inc.
- 2000 16th Street
- Denver
- Colorado
- 80202
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| DVA | NYSE (New York Stock Exchange) | Yes | Common Stock | US | USD | Oct 1995 |
| TRL | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 1995 |
| 0I7E | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Oct 1995 |
| DVA * | BMV (Bolsa Mexicana de Valores) | Yes | Common Stock | MX | MXN | Oct 1995 |
| DVAI34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH REP 1 COM USD0.001 | BR | BRL | May 2019 |
Biography
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab ser...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 23:32 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.